

Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1)
Recombinant Antibody
Catalog # APR10996

Specification

Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	Q96D31
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2SA
Calculated MW	150 KDa

Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) - Additional Information

Target/Specificity

Orai1

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) - Protein Information

Name ORAI1 {ECO:0000303|PubMed:16921383, ECO:0000312|HGNC:HGNC:25896}

Function

Pore-forming subunit of two major inward rectifying Ca(2+) channels at the plasma membrane: Ca(2+) release-activated Ca(2+) (CRAC) channels and arachidonate-regulated Ca(2+)-selective (ARC) channels (Probable) (PubMed:16645049, PubMed:16733527, PubMed:16807233, PubMed:16921383, PubMed:19249086, PubMed:19706554, PubMed:23307288, PubMed:26956484, PubMed:28219928). Assembles with ORAI2 and ORAI3 to form hexameric CRAC

channels that mediate Ca(2+) influx upon depletion of endoplasmic reticulum Ca(2+) store and channel activation by Ca(2+) sensor STIM1, a process known as store-operated Ca(2+) entry (SOCE). Various pore subunit combinations may account for distinct CRAC channel spatiotemporal and cell-type specific dynamics. ORAI1 mainly contributes to the generation of Ca(2+) plateaus involved in sustained Ca(2+) entry and is dispensable for cytosolic Ca(2+) oscillations, whereas ORAI2 and ORAI3 generate oscillatory patterns. CRAC channels assemble in Ca(2+) signaling microdomains where Ca(2+) influx is coupled to calmodulin and calcineurin signaling and activation of NFAT transcription factors recruited to ORAI1 via AKAP5. Activates NFATC2/NFAT1 and NFATC3/NFAT4-mediated transcriptional responses. CRAC channels are the main pathway for Ca(2+) influx in T cells and promote the immune response to pathogens by activating NFAT-dependent cytokine and chemokine transcription (PubMed:16582901, PubMed:17442569, PubMed:19182790, PubMed:20354224, PubMed:22641696, PubMed:26221052, PubMed:32415068, PubMed:33941685). Assembles with ORAI3 to form channels that mediate store-independent Ca(2+) influx in response to inflammatory metabolites arachidonate or its derivative leukotriene C4, termed ARC and LRC channels respectively (PubMed:19622606, PubMed:32415068). Plays a prominent role in Ca(2+) influx at the basolateral membrane of mammary epithelial cells independently of the Ca(2+) content of endoplasmic reticulum or Golgi stores. May mediate transepithelial transport of large quantities of Ca(2+) for milk secretion (By similarity) (PubMed:20887894).

Cellular Location

Cell membrane; Multi-pass membrane protein. Basolateral cell membrane {ECO:0000250|UniProtKB:Q8BWG9}; Multi-pass membrane protein. Note=Upon store depletion, colocalizes with STIM1 in membrane punctae at ER-PM junctions (PubMed:19182790, PubMed:19249086, PubMed:26221052, PubMed:27185316) [Isoform beta]: Cell membrane

Tissue Location


Expressed in naive CD4 and CD8 T cells (at protein level) (PubMed:26956484). Expressed at similar levels in naive and effector T helper cells (PubMed:20354224)

Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) - Images



Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-Orai1 Reference Antibody (Amgen patent anti-ORAI1) is more than 95%, determined by SEC-HPLC.